Baylor Scott & White Charles A. Sammons Cancer Center | Strategic Alliance Partners

Different subsets of patients with estrogen receptor-positive breast cancer achieved better pathologic complete response rates with neoadjuvant pembrolizumab/chemotherapy vs placebo/chemotherapy.

An implementation of nursing practice changes helped improve the fall rates among patients being treated by the surgical oncology team.

CDK4/6 inhibitors have demonstrated promise in treating patients with estrogen receptor (ER)–positive, HER2-negative breast cancer in both a neoadjuvant and adjuvant setting.

"Clinical trials are the vital bridge between research and a drug’s eventual availability to patients."